Tanisi Pharma

Tanisi Pharma is a biopharmaceutical company focused on the development of non-opioid therapeutics for the treatment of chronic pain. The company's lead candidate, TNP-001, is a peripherally restricted small molecule inhibitor of the Nav1.7 sodium channel, designed to treat neuropathic pain conditions without the side effects associated with central nervous system-acting drugs. Founded by experts from Johns Hopkins University, Tanisi Pharma aims to address the opioid crisis by providing effective alternatives for pain management. Their research specifically targets conditions like erythromelalgia and diabetic neuropathy. The company is currently advancing its lead program through preclinical development toward clinical trials.